Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.

doi:10.1158/1078-0432.CCR-22-3930

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Nov 2023

Singh Harshabad, Keller Rachel B, Kapner Kevin S, Dilly Julien, Raghavan Srivatsan, Yuan Chen, Cohen Elizabeth F, Tolstorukov Michael, Andrews Elizabeth, Brais Lauren K, da Silva Annacarolina, Perez Kimberly, Rubinson Douglas A, Surana Rishi, Giannakis Marios, Ng Kimmie, Clancy Thomas E, Yurgelun Matthew B, Schlechter Benjamin L, Clark Jeffrey W, Shapiro Geoffrey I, Rosenthal Michael H, Hornick Jason L, Nardi Valentina, Li Yvonne Y, Gupta Hersh, Cherniack Andrew D, Meyerson Matthew, Cleary James M, Nowak Jonathan A, Wolpin Brian M, Aguirre Andrew J

Abstract excerpt

PURPOSE: Approximately 8% to 10% of pancreatic ductal adenocarcinomas (PDAC) do not harbor mutations in KRAS. Understanding the unique molecular and clinical features of this subset of pancreatic cancer is important to guide patient stratification for clinical trials of molecularly targeted agents. EXPERIMENTAL DESIGN: We analyzed a single-institution cohort of 795 exocrine pancreatic cancer cases (including 785...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pancreatic and Hepatic Oncology Research

Share to Pancreatic Neoplasms

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 37463056
DOI: 10.1158/1078-0432.CCR-22-3930
PMCID: PMC10795103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.PMID 37463056Read ↗

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.Semantic proximity Read ↗

Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.Semantic proximity Read ↗

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities.Semantic proximity Read ↗

Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genesSemantic proximity Read ↗

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read ↗

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition.Semantic proximity Read ↗

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.Semantic proximity Read ↗

Precision medicine for KRAS wild-type pancreatic adenocarcinomas.Semantic proximity Read ↗

KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential.Semantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.